Pulmatrix Management

How has Ted Raad's remuneration changed compared to Pulmatrix's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$692k	US$567k	-US$14m
Sep 30 2023	n/a	n/a	-US$16m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$1m	US$525k	-US$19m
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$1m	US$480k	-US$23m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$19m
Dec 31 2020	US$2m	US$464k	-US$19m
Sep 30 2020	n/a	n/a	-US$20m
Jun 30 2020	n/a	n/a	-US$13m
Mar 31 2020	n/a	n/a	-US$20m
Dec 31 2019	US$823k	US$411k	-US$21m
Sep 30 2019	n/a	n/a	-US$21m
Jun 30 2019	n/a	n/a	-US$22m
Mar 31 2019	n/a	n/a	-US$20m
Dec 31 2018	US$707k	US$345k	-US$21m
Sep 30 2018	n/a	n/a	-US$21m
Jun 30 2018	n/a	n/a	-US$20m
Mar 31 2018	n/a	n/a	-US$20m
Dec 31 2017	US$963k	US$216k	-US$18m

Compensation vs Market: Ted's total compensation ($USD691.89K) is about average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Ted's compensation has been consistent with company performance over the past year.

CEO

Ted Raad (53 yo)

5yrs

Tenure

US$691,888

Compensation

Mr. Teofilo David Raad, also known as Ted, MBA, has been Director at Oxeia Biopharmaceuticals Inc. since 2021. Mr. Raad serves as Chief Executive Officer, President and Director at Pulmatrix, Inc. since Ma...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Teofilo Raad	President	5yrs	US$691.89k	no data
Peter Ludlum	Interim CFO and Principal Accounting & Financial Officer	2.1yrs	US$510.22k	no data
Alexander Klibanov	Founder	21.3yrs	no data	no data

5.0yrs

Average Tenure

68yo

Average Age

Experienced Management: PULM's management team is seasoned and experienced (5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Teofilo Raad	President	5yrs	US$691.89k	no data
Michael Higgins	Independent Chairman	8.9yrs	US$92.97k	0% $ 0
David Denning	Member of Pulmazole Clinical Advisory Board	no data	no data	no data
Christopher Cabell	Independent Director	3.9yrs	US$50.56k	0% $ 0
Jonathan Corren	Member of Pulmazole Clinical Advisory Board	no data	no data	no data
Richard Batycky	Independent Director	4.5yrs	US$59.56k	0.00068% $ 47.2
Todd Bazemore	Independent Director	3.6yrs	US$58.06k	0% $ 0
Ritesh Agarwal	Member of Pulmazole Clinical Advisory Board	no data	no data	no data
Cendrine Godet	Member of Pulmazole Clinical Advisory Board	no data	no data	no data
David Stevens	Member of Pulmazole Clinical Advisory Board	no data	no data	no data
William Calhoun	Chair of PUR1900 & PUR1800 Clinical Advisory Board	no data	no data	no data
Stephen Silberstein	Chair of PUR3100 (DHE) Clinical Advisory Board	no data	no data	no data

4.5yrs

Average Tenure

53yo

Average Age

Experienced Board: PULM's board of directors are considered experienced (4.5 years average tenure).

Pulmatrix Management

Management criteria checks 4/4

Key information

Recent management updates

Insufficient new directors

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Recent updates

Full year 2023 earnings released: US$3.87 loss per share (vs US$5.46 loss in FY 2022)

Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis

Insufficient new directors

Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Consensus revenue estimates increase by 16%

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix, Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates upgraded to US$4.94 loss, revenue downgraded

First quarter 2023 earnings released: US$1.22 loss per share (vs US$1.51 loss in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix, Inc. Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces Patient Dosing Completed for Its Novel Inhaled Therapy PUR3100 for Acute Migraine

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pulmatrix, Inc. Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix doses first subjects in phase 1 trial of acute migraine treatment PUR3100

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pulmatrix, Inc., Annual General Meeting, Jun 15, 2022

Price target decreased to US$10.00

No longer forecast to breakeven

Pulmatrix Appoints Peter Ludlum as Interim Chief Financial Officer

Price target increased to US$200

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Pulmatrix, Inc. Appoints Dr. Margaret Wasilewski as Chief Medical Officer

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Invest In Growth?

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.31 loss in 3Q 2020)

Is Pulmatrix (NASDAQ:PULM) In A Good Position To Deliver On Growth Plans?

Pulmatrix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Consensus revenue estimates increase to US$8.85m

Pulmatrix, Inc.'s (NASDAQ:PULM) Sole Analyst Just Made A Massive Upgrade To Their Forecasts

Earnings Beat: Pulmatrix, Inc. (NASDAQ:PULM) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Second quarter 2021 earnings released: US$0.068 loss per share (vs US$0.048 loss in 2Q 2020)

Independent Director Mark Iwicki has left the company

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

Consensus revenue estimates increase to US$6.45m

First quarter 2021 earnings released: US$0.089 loss per share (vs US$0.23 loss in 1Q 2020)

Independent Director has left the company

Full year 2020 earnings released: US$0.67 loss per share (vs US$1.23 loss in FY 2019)

Pulmatrix Provides Pipeline and Business Update

We're Not Very Worried About Pulmatrix's (NASDAQ:PULM) Cash Burn Rate

New 90-day high: US$1.84

New 90-day high: US$1.41

New 90-day high: US$1.28

Third quarter 2020 earnings released: US$0.31 loss per share

Earnings beat expectations

Price target lowered to US$10.00

Pulmatrix, Inc. Appoints Todd Bazemore to Its Board of Directors, Effective October 1, 2020

Pulmatrix, Inc. Provides an Update on Product Pipeline

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age